受强制性开放获取政策约束的文章 - Diah Mey了解详情
可在其他位置公开访问的文章：5 篇
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination …
C Driessen, M Kraus, M Joerger, H Rosing, J Bader, F Hitz, C Berset, ...
Haematologica 101 (3), 346, 2016
强制性开放获取政策： Swiss National Science Foundation
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
R Benz, K Arn, M Andres, T Pabst, M Baumann, U Novak, F Hitz, U Hess, ...
Blood advances 4 (15), 3699-3707, 2020
强制性开放获取政策： Swiss Cancer Foundation, Swiss Cancer League
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the …
U Novak, M Fehr, S Schär, M Dreyling, C Schmidt, E Derenzini, T Zander, ...
EClinicalMedicine 64, 2023
强制性开放获取政策： Swiss Cancer Foundation
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
A Stathis, U Mey, S Schär, F Hitz, C Pott, N Mach, F Krasniqi, U Novak, ...
Blood advances 6 (13), 3911-3920, 2022
强制性开放获取政策： Swiss Cancer Foundation
Alternate-day dosing of pomalidomide in relapsed/refractory multiple myeloma: a multicenter, single-arm phase 2 trial
T Zander, T Pabst, S Schär, S Aebi, U Mey, U Novak, E Lerch, ...
Leukemia 37 (3), 699-701, 2023
强制性开放获取政策： Swiss Cancer League
出版信息和资助信息由计算机程序自动确定